Top Pharmaceutical Companies by Revenue in 2026 to 27

A single obesity drug franchise reshuffled the entire pharmaceutical revenue leaderboard within roughly eighteen months. Eli Lilly, ranked tenth among global pharmaceutical companies by revenue just two years earlier, climbed to the number one position on the strength of Mounjaro and Zepbound, its diabetes and obesity treatments, displacing companies that had held top-tier positions for decades.

That kind of movement illustrates something important about pharmaceutical revenue rankings: they are not a static hierarchy reflecting permanent corporate strength, but a snapshot of which therapeutic categories are currently driving growth, which patents are approaching expiration, and which companies successfully translated research investment into blockbuster products at exactly the right moment.

Reading that snapshot accurately requires more care than simply copying a headline ranking, because the underlying methodology varies enormously between sources. A company’s total corporate revenue, spanning pharmaceuticals, medical devices, diagnostics, and consumer health products in diversified conglomerates like Johnson & Johnson, tells a very different story than its pharmaceutical-segment revenue alone. Fiscal years differ across companies, with most reporting on a standard calendar year while Takeda, for instance, reports on an April-to-March fiscal year that straddles two calendar years. Currency conversion introduces further variation, since companies reporting in euros, Swiss francs, or Japanese yen see their dollar-equivalent figures shift with exchange rates independent of any change in their actual underlying business performance. This ranking uses pharmaceutical segment revenue, meaning prescription drug and vaccine sales specifically, excluding diversified business lines like medical devices or diagnostics, based on the most recently completed fiscal year figures available from company annual reports and industry tracking services at the time of publication.

How This Revenue List Is Calculated

Company selection for this ranking prioritizes publicly traded pharmaceutical and biopharmaceutical companies with substantial global prescription drug sales, based on data compiled from company annual reports and industry tracking services including GlobalData and GetReskilled’s pharmaceutical industry analysis.

Revenue figures reflect pharmaceutical segment sales specifically wherever a company reports that breakdown separately, meaning Johnson & Johnson’s figure reflects its Innovative Medicine segment rather than its combined pharmaceutical and MedTech total, and Roche’s figure reflects its pharmaceuticals division rather than its combined pharmaceuticals and diagnostics total. Most companies in this ranking report on a standard calendar fiscal year ending December 31; Takeda is a notable exception, reporting on a fiscal year running from April through March.

Currency conversion to U.S. dollars follows each source’s own reporting methodology, meaning companies reporting natively in euros, Swiss francs, British pounds, or yen carry some inherent exchange-rate-driven variance that reflects currency movement as much as underlying business performance.

Where full-year 2025 pharmaceutical-segment figures were available, they are used; for several companies further down the ranking, the most recently available complete-year pharmaceutical revenue figure is 2024, and this is noted explicitly in the table below rather than presented as more current than it actually is.

Top 20 Pharmaceutical Companies by Revenue

*Figures marked FY2024 reflect the most recently available complete-year data at time of publication and readers are adviced to verify it against each company’s most recent annual report for updated FY2025 figures.

The Companies at the Top of the Revenue Table

Diversified Pharmaceutical Groups

Johnson & Johnson and Roche both operate substantial non-pharmaceutical business lines, medical technology for J&J and diagnostics for Roche, which is precisely why isolating their pharmaceutical-segment revenue specifically, rather than citing their much larger total corporate revenue figures, matters for a fair pharmaceutical-industry comparison. A ranking using J&J’s full corporate revenue, which exceeds $90 billion when medical technology is included, would overstate its position relative to companies with no comparable diversified business line.

Biopharmaceutical Specialists

Companies including Eli Lilly, AbbVie, Amgen, and Gilead Sciences derive the substantial majority or entirety of their revenue from pharmaceutical and biologic drug sales, making their reported figures more directly comparable to each other without the segment-isolation adjustments diversified conglomerates require.

Vaccine and Infectious Disease Leaders

Pfizer’s historical vaccine leadership, extending from its COVID-19 vaccine portfolio into broader infectious disease and immunology franchises, and Gilead’s concentrated strength in HIV and viral hepatitis treatment illustrate how a company’s therapeutic area concentration shapes both its revenue stability and its exposure to specific competitive and patent-related risks.

Companies With Large Consumer or Medical Device Businesses

Beyond Johnson & Johnson, companies like Bayer maintain substantial non-pharmaceutical operations, in Bayer’s case spanning crop science and consumer health alongside its pharmaceutical division, reinforcing why segment-specific revenue reporting, rather than total corporate revenue, provides the more meaningful basis for pharmaceutical industry comparison specifically.

The Global Market Behind This Ranking

The companies in this table are competing within a global pharmaceutical market valued at approximately $1.74 trillion in 2025, projected to reach roughly $2.78 trillion by 2033 at a compound annual growth rate near 6.1 percent, according to industry market-sizing estimates. North America alone accounts for an estimated 41.8 percent of global pharmaceutical revenue, reflecting both the sheer size of the U.S. prescription drug market and the pricing environment that has historically made it the most lucrative single market for nearly every company in this ranking.

That concentration also explains why U.S. policy developments, including Medicare Part D price negotiation under the Inflation Reduction Act and “most favored nation” pricing proposals, carry outsized weight in shaping individual company revenue guidance, a dynamic that shows up repeatedly in the company-specific breakdowns below.

Company-by-Company Breakdown: What Put Each One at the Top

Revenue rankings compress an enormous amount of company-specific detail into a single number, and understanding what actually sits behind each figure, which drugs are doing the heavy lifting, which patents are under threat, and which strategic bets paid off, reveals considerably more than the ranking alone.

Eli Lilly

Eli Lilly reached the number one position almost entirely on the strength of tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. In the first quarter of 2025 alone, the two brands generated a combined $6.15 billion, accounting for roughly 48 percent of Lilly’s total quarterly revenue, a concentration that shows just how dominant this single molecule has become for the company.

Lilly has aggressively expanded manufacturing capacity to meet demand and has continued building out its oncology franchise around Verzenio, but tirzepatide’s trajectory against Novo Nordisk’s competing GLP-1 franchise remains the single most important variable in Lilly’s continued position at the top of this ranking.

Pfizer

Pfizer has spent the past two years managing the steep decline of its COVID-19 franchise, Comirnaty and Paxlovid, from their extraordinary pandemic-era peak toward a much smaller, more normalized base of revenue.

Offsetting that decline has required leaning on Eliquis, the blood thinner co-marketed with Bristol Myers Squibb, cardiomyopathy treatment Vyndaqel, and an oncology portfolio substantially expanded by the 2023 acquisition of Seagen for approximately $43 billion, which added antibody-drug conjugates including Padcev, Adcetris, and Tukysa to Pfizer’s cancer pipeline.

AbbVie

AbbVie delivered one of the pharmaceutical industry’s more closely watched turnaround stories, successfully offsetting the biosimilar-driven collapse of Humira, once the best-selling drug in the world, with rapid growth from its next-generation immunology franchise.

Skyrizi alone generated $17.56 billion in sales, and AbbVie’s combined immunology portfolio brought in $30.41 billion, demonstrating that a company can survive even its single largest product losing patent protection if the pipeline behind it is deep enough.

Johnson & Johnson

Johnson & Johnson’s Innovative Medicine division grew to $60.4 billion, up from $56.9 billion in 2024, even as the company confronts two simultaneous headwinds: the loss of U.S. exclusivity for Stelara, previously its second-largest seller, and the direct impact of Medicare Part D price negotiation, since three of the first ten drugs selected for negotiation under the Inflation Reduction Act are J&J products. Growth drivers offsetting this pressure include Darzalex in multiple myeloma, Tremfya in immunology, and Carvykti, J&J’s CAR-T cell therapy.

AstraZeneca

AstraZeneca posted $58.73 billion in revenue, up 8.6 percent from $54.10 billion the prior year, with growth spread unusually broadly across its portfolio rather than concentrated in a single blockbuster: oncology revenue rose 22 percent, cardiovascular, renal and metabolism revenue rose 21 percent, respiratory and immunology rose 24 percent, and rare disease revenue climbed 14 percent across the first nine months of the most recent reporting period. Farxiga, a diabetes and heart failure treatment, alone generated $8.4 billion.

Merck & Co.

Merck & Co. remains built almost entirely around a single extraordinary asset: Keytruda, which generated approximately $31.6 billion in sales, retaining its position as the world’s best-selling drug for a third consecutive year across more than 40 approved indications. That concentration is also Merck’s greatest long-term vulnerability, since Keytruda’s patent protection is expected to lapse later this decade, making the successful development of next-generation oncology and vaccine assets, including its Gardasil HPV vaccine franchise, central to the company’s post-Keytruda strategy.

Roche’s

Roche’s pharmaceutical division reached $57.57 billion, part of total company revenue of roughly CHF 68.7 billion, with more than 70 percent of that total generated by pharmaceuticals rather than Roche’s diagnostics business. Vabysmo, an eye disease treatment for wet age-related macular degeneration and diabetic macular edema, has emerged as a particularly important growth driver, competing directly against Regeneron’s Eylea, alongside continued strength from multiple sclerosis treatment Ocrevus and hemophilia therapy Hemlibra.

Novartis

Novartis generated $54.53 billion in its first full year operating as a streamlined, standalone medicines company following the 2023 spinoff of its generics and biosimilars unit, Sandoz. That restructuring sharpened Novartis’s focus on branded innovative medicines including Cosentyx in immunology, Kisqali in breast cancer, and Entresto in heart failure, though Entresto’s recent loss of patent exclusivity has introduced new competitive pressure the company is actively managing.

Bristol Myers Squibb

Bristol Myers Squibb reported $48.19 billion in revenue while simultaneously guiding investors to expect a low-to-mid single-digit revenue decline for the coming fiscal year, a rare and unusually candid acknowledgment of how directly patent expiration across multiple key products, including continued erosion of Revlimid and shared exposure to Eliquis, is reshaping the company’s near-term outlook. Newer growth drivers including Camzyos, Breyanzi, and the newly launched schizophrenia treatment Cobenfy represent BMS’s attempt to rebuild its growth base ahead of further patent cliffs.

Sanofi

Sanofi reached $47.42 billion in revenue, with Dupixent, its immunology blockbuster co-developed and profit-shared with Regeneron, standing as the company’s single most important growth engine, crossing well over $13 billion in annual sales and continuing to expand into new approved indications including chronic spontaneous urticaria. Sanofi’s vaccine franchise provides a second, more stable revenue base alongside its more dynamic specialty pharmaceutical portfolio.

Novo Nordisk

Novo Nordisk generated $44.97 billion, with Ozempic and Wegovy together accounting for roughly 66 percent of total company revenue in early 2025 reporting periods. Wegovy sales rose 56 percent to DKK 65.1 billion in 2024, but 2025 brought a sharp change in trajectory: the company repeatedly cut its full-year sales guidance, citing slower-than-expected U.S. obesity market expansion, persistent unauthorized compounded semaglutide competition, and intensifying competitive pressure from Eli Lilly’s Zepbound, which has surpassed Wegovy in U.S. prescription volume.

Novo’s market value fell from a peak near $615 billion to roughly $310 billion during this period, illustrating how quickly investor sentiment can shift even for a company with genuinely strong absolute sales growth.

GSK

GSK reached $41.95 billion, anchored by its vaccine franchise, particularly Shingrix for shingles prevention and the RSV vaccine Arexvy, alongside a specialty HIV portfolio operated substantially through its majority-owned ViiV Healthcare joint venture, a business line that gives GSK a distinctive revenue mix compared to peers more heavily weighted toward oncology or immunology.

Amgen

Amgen generated $36.80 billion, built around a portfolio spanning bone health treatments Prolia and Evenity, cholesterol-lowering Repatha, and its legacy biologic Enbrel, which continues facing gradual biosimilar erosion. Amgen has also moved into the obesity treatment race with its pipeline candidate MariTide, an area where success or failure could materially reshape the company’s position in future rankings.

Takeda

Takeda, Japan’s largest pharmaceutical company by revenue, reached $30.14 billion on its April-to-March fiscal year, driven substantially by Entyvio, its flagship treatment for inflammatory bowel disease, alongside a rare disease and plasma-derived therapy portfolio that has become an increasingly important part of the company’s overall growth strategy.

Gilead Sciences

Gilead Sciences generated $29.40 billion, with Biktarvy, its combination HIV treatment, alone contributing $14.3 billion and commanding more than 52 percent of the entire U.S. HIV treatment market. Gilead has continued diversifying beyond its historical HIV and hepatitis strength into oncology through Trodelvy and into HIV prevention through long-acting lenacapavir, marketed as Yeztugo.

Boehringer Ingelheim

Boehringer Ingelheim, a privately held German company that does not trade on any public stock exchange, generated approximately $22.83 billion, with Jardiance, a diabetes and heart failure treatment co-marketed with Eli Lilly, and Ofev, a pulmonary fibrosis treatment, standing as its most significant revenue contributors.

Bayer’s

Bayer’s pharmaceutical division reached approximately $18.88 billion, driven by Xarelto, a blood thinner co-marketed with Johnson & Johnson, and Eylea, which Bayer markets outside the United States under its collaboration with Regeneron.

Bayer’s overall corporate financial picture, however, has been significantly complicated by substantial ongoing litigation liabilities tied to its Roundup herbicide business, a reminder that a company’s pharmaceutical segment performance does not always reflect its total corporate financial health.

Teva Pharmaceuticals

Teva Pharmaceuticals, headquartered in Israel, generated approximately $16.54 billion as the world’s largest manufacturer of generic medicines by volume, a fundamentally different business model than the innovator-focused companies dominating the top of this ranking. Teva has increasingly supplemented its generics base with branded specialty products including Austedo for movement disorders and Ajovy for migraine prevention.

CSL

CSL, an Australian biotechnology company, reached approximately $15.23 billion, generated primarily through its CSL Behring plasma-derived therapy division, alongside CSL Seqirus, a major influenza vaccine manufacturer, and CSL Vifor, focused on kidney disease treatment.

CSL’s total revenue grew 7.41 percent year over year, with a December regulatory milestone for its hereditary angioedema treatment Andembry marking a key rare disease pipeline advance.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals generated approximately $14.20 billion, historically dominated by Eylea and Eylea HD, which together represented 42 percent of total company revenue in 2024, though that concentration has become a genuine vulnerability following the May 2024 expiration of Eylea’s core U.S. regulatory exclusivity and the subsequent arrival of biosimilar competitors including Amgen’s Pavblu.

Dupixent, Regeneron’s profit-shared immunology partnership with Sanofi, has increasingly offset that pressure, representing 32 percent of total revenue in 2024 and continuing to grow at a faster rate than Eylea as it expands into additional approved indications.

Revenue Does Not Tell the Whole Story

A company’s revenue ranking says relatively little about its underlying profitability, research and development investment intensity, market capitalization, pipeline strength, geographic revenue concentration, upcoming patent expirations, or recent acquisition activity, all of which shape a company’s actual competitive position and future trajectory considerably more than its current top-line revenue figure alone.

A company generating strong current revenue from a small number of products approaching patent expiration faces a materially different outlook than a company with more modest current revenue but a deep, diversified late-stage pipeline.

None of these additional factors are incorporated into the revenue ranking above, and readers evaluating pharmaceutical companies for investment or competitive analysis purposes should treat this revenue snapshot as one input among several rather than a comprehensive assessment of company strength.

Which Therapeutic Areas Drive the Biggest Revenue Streams?

Obesity and diabetes treatment, driven overwhelmingly by GLP-1 receptor agonist drugs, has emerged as the fastest-growing major therapeutic category in recent years, directly fueling Eli Lilly’s rise to the top revenue position and Novo Nordisk’s continued strength despite recent workforce reductions tied to competitive and pricing pressure in that same category. Oncology remains one of the largest and most consistently invested therapeutic areas across nearly every major company in this ranking.

Immunology, anchored by blockbuster franchises like AbbVie’s Skyrizi and Rinvoq and Sanofi’s Dupixent, continues to generate substantial revenue as these newer-generation treatments replace older therapies facing biosimilar competition. Vaccines, cardiovascular disease treatment, and rare disease therapies round out the major revenue-generating categories represented across this group of companies.

How Patent Expirations and New Drugs Can Shift Revenue

Patent cliffs, the period when a blockbuster drug loses market exclusivity and faces generic or biosimilar competition, represent one of the most significant recurring threats to pharmaceutical company revenue, and companies actively restructure their commercial strategies and pipeline investment specifically to manage this risk.

Biosimilar and generic competition typically erodes a formerly protected drug’s revenue rapidly once exclusivity ends, sometimes within a single fiscal year. New drug launches and label expansions into additional approved indications represent the primary mechanism by which companies replace revenue lost to expiring patents.

Bristol Myers Squibb’s own 2026 guidance, anticipating a low to mid single digit revenue decline tied to multiple key products facing patent expiration, illustrates how directly and immediately this dynamic can affect a major company’s near-term outlook. Pricing and reimbursement negotiations, increasingly shaped by regulatory changes in major markets including the United States, add a further layer of revenue variability that operates somewhat independently of a company’s underlying commercial or scientific execution.

How Revenue Has Changed Over Time

The most dramatic recent shift in this ranking has been Eli Lilly’s ascent from roughly tenth position to first within a relatively short span, driven almost entirely by explosive demand growth for its GLP-1 obesity and diabetes franchise. Novo Nordisk, despite reporting continued sales growth in its native Danish krone, saw its U.S. dollar-denominated revenue figure remain comparatively flat due to currency movement, illustrating how exchange rate effects can obscure genuine underlying business performance when comparing figures across companies reporting in different currencies.

Johnson & Johnson’s pharmaceutical segment revenue has grown steadily, though its position in a pharmaceutical-segment-only ranking sits lower than its total corporate revenue figure would suggest, precisely because that total figure includes its substantial medical technology business. Analyst commentary heading into 2026 anticipates continued divergence in growth trajectories across this group, with most major companies guiding toward single-digit revenue growth while a smaller number, Eli Lilly prominent among them, continue projecting more substantial expansion tied to their obesity and metabolic disease franchises specifically.

Important Limitations of a Pharma Revenue Ranking

Fiscal year mismatches, particularly Takeda’s April-to-March reporting period relative to the calendar-year reporting most other companies in this ranking use, mean that direct side-by-side comparison always involves some degree of temporal approximation rather than a perfectly synchronized snapshot.

Currency effects introduce further distortion for any company reporting natively in a currency other than U.S. dollars, since a company’s dollar-denominated revenue figure can rise or fall meaningfully due to exchange rate movement alone, independent of any actual change in unit sales or pricing. Diversification across pharmaceutical and non-pharmaceutical business lines, as seen with Johnson & Johnson, Roche, and Bayer, requires deliberate segment isolation to produce a fair pharmaceutical-industry comparison, and different data sources do not always apply that isolation consistently.

Differing reporting standards between companies headquartered in different countries, along with the inherent lag between a fiscal year’s close and the eventual publication of finalized, audited annual report figures, mean that any revenue ranking compiled at a specific point in time should be understood as a best available snapshot rather than a permanently fixed hierarchy, one that shifts meaningfully as new annual reports are published and as major new drug launches or patent expirations continue to reshape the competitive landscape from one year to the next.

Revenue rankings like this one offer a genuinely useful snapshot of scale and momentum within the global pharmaceutical industry, and the dramatic recent reshuffling driven by GLP-1 obesity treatments demonstrates just how quickly that snapshot can change when a single therapeutic breakthrough captures sufficient global demand. What the ranking cannot capture on its own, profitability, pipeline depth, patent exposure, and long-term competitive positioning, matters just as much to understanding where any individual company actually stands, which is why revenue should be read as a starting point for further analysis rather than a complete verdict on pharmaceutical industry leadership.

The artilce is based on most recently available fiscal year data at time of publication. Readers are adviced to further verfity the data against current company annual reports for the latest reporting period.

FAQ

Q: Which pharmaceutical companies have the highest revenue?

A: As of the most recent full fiscal year data available, Eli Lilly, Pfizer, and AbbVie rank among the highest by pharmaceutical segment revenue, with Eli Lilly’s rise driven largely by its GLP-1 diabetes and obesity treatments.

Q: How is pharmaceutical company revenue calculated?

A: Revenue rankings typically use either total corporate revenue or pharmaceutical-segment-specific revenue, with the latter excluding non-pharmaceutical business lines like medical devices or diagnostics for diversified companies.

Q: What is the difference between total revenue and pharmaceutical revenue?

A: Total revenue includes all of a company’s business segments, while pharmaceutical revenue isolates prescription drug and vaccine sales specifically, which matters most for companies like Johnson & Johnson with substantial non-pharmaceutical operations.

Q: Why do pharma rankings change from year to year?

A: Rankings shift due to new blockbuster drug launches, patent expirations, currency fluctuations, mergers and acquisitions, and shifting demand across therapeutic categories such as the recent surge in GLP-1 obesity treatments.

Q: How do patent expirations affect pharmaceutical revenue?

A: When a drug’s patent expires, generic or biosimilar competition typically erodes its revenue rapidly, sometimes within a single fiscal year, making pipeline replacement critical to sustaining overall company revenue.

Q: Does revenue equal pharmaceutical company profit?

A: No. Revenue reflects total sales, while profit accounts for research and development costs, manufacturing, administrative expenses, and other costs, meaning a high-revenue company is not automatically the most profitable.

Q: How do acquisitions affect pharma rankings?

A: Acquisitions can rapidly boost a company’s revenue by adding an acquired company’s product portfolio, though the full revenue impact often takes one or more fiscal years to fully reflect in reported figures.

Q: Why do pharmaceutical companies report different fiscal years?

A: Most companies use a standard calendar fiscal year, but some, including Takeda, use a non-calendar fiscal year based on their home country’s corporate reporting conventions, requiring careful comparison across rankings.